Francis Duhay
Known title: DirectorCIK: 0001760582
Francis Duhay's purchase track record
Francis Duhay has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/31/2024 | NVNO | $250K | -15.6% | +31.8% | +5.4% |
| 8/16/2022 | NVNO | $48K | +5.7% | +4.3% | -3.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NVNO | ▼ Sell | Open Market | 11 | $123 | 9/11/2026 | View on chart |
| NVNO | ▼ Sell | Open Market | 140 | $1K | 6/11/2026 | View on chart |
| NVNO | ▼ Sell | Open Market | 140 | $2K | 3/12/2026 | View on chart |
| NVNO | ▼ Sell | Open Market | 4,900 | $2K | 12/11/2025 | View on chart |
| NVNO | ▼ Sell | Open Market | 4,900 | $4K | 9/15/2025 | View on chart |
| NVNO | ▲ Buy | Open Market | 81,433 | $250K | 12/31/2024 | View on chart |
| NVNO | ▲ Buy | Open Market | 7,751 | $48K | 8/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
enVVeno Medical to Showcase enVVe System at VEINS 2026 Summit
enVVeno Medical Corporation announced that its first-in-class enVVe system will be featured at The VEINS 2026 Innovation Summit. This event highlights the company's progress as it moves toward a U.S. pivotal trial for its medical technology. The announcement serves as a key milestone in the development timeline for the device.
enVVeno Medical to Showcase enVVe System at VEINS 2026 Summit. enVVeno Medical Corporation announced that its first-in-class enVVe system will be featured at The VEINS 2026 Innovation Summit. This event highlights the company's progress as it moves toward a U.S. pivotal trial for its medical technology. The announcement serves as a key milestone in the development timeline for the device.